Dragonfly Expands Research Collaboration With Abbvie To Develop Novel Therapeutic Candidates For Immune-Mediated Diseases

Dragonfly Therapeutics. (Dragonfly), A Biotechnology Company, Announced An Expansion Of Its Research Collaboration With Abbvie To Discover And Develop Dragonfly'S Novel Immunotherapies For New Targets In Autoimmune And Fibrotic Diseases.Abbvie Successfully Licensed Its First Trinket Drug Candidate From Dragonfly, Part Of A Multi-Target Collaboration Initiated In November 2019, In January 2021."Abbvie Is Committed To Delivering Transformative Treatment Options For Patients Suffering From Autoimmune And Fibrotic Diseases," Said Dr. Jonathon Sedgwick, Vice President And Global Head Of Discovery Research At Abbvie. "We Have Seen Strong Progress In Our Current Collaboration With Dragonfly Focused On Their Trinket Technology And Are Pleased To Expand Our Partnership To Include Additional Immunology Targets Of Interest To Abbvie.""Abbvie Is A Global Leader In Treating Immune-Mediated Diseases, And They Continue To Be A Terrific Partner" Said Bill Haney, Co-Founder And Chief Executive Officer Of Dragonfly, "We Look Forward To Building On Our Successful Collaboration, And Rapidly Progressing With The Abbvie Team To Advance New Treatment Options For Patients."Under The Agreement, Dragonfly Will Grant Abbvie The Option To License Exclusive Worldwide Intellectual Property Rights To Multiple New Candidates Developed Using Dragonfly'S Trinket Technology Platform. Abbvie Will Pay Dragonfly An Upfront Payment, Future Success-Based Milestone Payments And Royalties.Dragonfly Therapeutics, Inc. Is A Clinical-Stage Biopharmaceutical Company Committed To Discovering, Developing And Commercializing Therapies That Use Its Novel Trinket Technology To Harness The Body'S Innate Immune System To Bring Breakthrough Treatments To Patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!